Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Avalo Therapeutics's share price for the quarter that ended in Mar. 2026 was €12.84. Avalo Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 24.64 Mil. Therefore, Avalo Therapeutics's market cap for the quarter that ended in Mar. 2026 was €316.35 Mil.
Avalo Therapeutics's quarterly market cap
increased
from Sep. 2025 (€193.97 Mil) to Dec. 2025 (€287.32 Mil) and
increased
from Dec. 2025 (€287.32 Mil) to Mar. 2026 (€316.35 Mil).
Avalo Therapeutics's annual market cap
increased
from Dec. 2023 (€9.14 Mil) to Dec. 2024 (€82.21 Mil) and
increased
from Dec. 2024 (€82.21 Mil) to Dec. 2025 (€287.32 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Avalo Therapeutics's Enterprise Value for Today is €770.43 Mil.
Avalo Therapeutics (STU:C6K0) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Avalo Therapeutics Market Cap Related Terms
Avalo Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Avalo Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:C6K0 vs SANA, ANRO, REPL: Market Cap Comparison
For the Biotechnology subindustry, Avalo Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avalo Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Avalo Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Avalo Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalo Therapeutics (STU:C6K0) has a Market Cap of €842.05 Mil as of Jul. 23, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Avalo Therapeutics and its competitors. According to the industry distribution chart, Avalo Therapeutics ranks #293 out of 1423 companies in the Biotechnology industry, placing it in the top 20.6%.
Is Avalo Therapeutics' Market Cap too high?
Avalo Therapeutics' current Market Cap is €842.05 Mil. Based on the distribution chart, Avalo Therapeutics ranks #293 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Avalo Therapeutics has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avalo Therapeutics' Market Cap compare to SANA and ANRO?
According to the Biotechnology industry distribution chart, Avalo Therapeutics ranks #293 out of 1423 companies for Market Cap. This places Avalo Therapeutics in the top 21% of its industry — outperforming the majority of peers. The industry median Market Cap is 112.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.15, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Avalo Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 112.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avalo Therapeutics's current Market Cap is €842.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Avalo Therapeutics (STU:C6K0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.02, compared to a current price of €15.76 — trading 78700% above its estimated fair value. The current Market Cap is €842.05 Mil. Avalo Therapeutics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Avalo Therapeutics (STU:C6K0), the current Market Cap is €842.05 Mil as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avalo Therapeutics (STU:C6K0) Overvalued in 2026?
Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued.
The current stock price of €15.76 is trading 78700% above its estimated GF Value™ of €0.02.
GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.
Key valuation signals for STU:C6K0:
Market Cap: €842.05 Mil
GF Value™: €0.02 vs. price of €15.76 (78700% above fair value)
No single metric tells the full story. See the STU:C6K0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
44GF Score
Get the complete analysis for STU:C6K0
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:C6K0 has been successfully added to your 
